Sun Pharmaceutical Industries, a leading Indian pharmaceutical company has started voluntary recall of multiple lots of Bupropion Hydrochloride Extended-release Tablets USP (SR), 200 mg, 60-count bottle, from the US market for failed dissolution specification. According to a USFDA notification, Sun Pharma's recall was initiated last month under Class-III classification which was as 'a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences'. Approximately 35,235 bottles (60 count) of Bupropion Hydrochloride extended-release tablets distributed by the company have been recalled.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.35 |
| Dr. Reddys Lab | 1236.85 |
| Cipla | 1232.80 |
| Zydus Lifesciences | 942.40 |
| Lupin | 2332.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: